CC
MRNA icon

Chicago Capital’s Moderna MRNA Stock Holding History

Chicago Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,955
Closed -$232K – 324
2024
Q2 		$232K Hold
1,955
– – 0.01% 283
2024
Q1 		$208K Sell
1,955
-197
-9% -$19.9K 0.01% 282
2023
Q4 		$214K Hold
2,152
– – 0.01% 260
2023
Q3 		$222K Hold
2,152
– – 0.01% 210
2023
Q2 		$261K Buy
2,152
+197
+10% +$26.3K 0.01% 196
2023
Q1 		$300K Hold
1,955
– – 0.01% 191
2022
Q4 		$351K Hold
1,955
– – 0.02% 180
2022
Q3 		$231K Sell
1,955
-33
-2% -$5.01K 0.01% 214
2022
Q2 		$284K Sell
1,988
-50
-2% -$7.15K 0.02% 205
2022
Q1 		$351K Hold
2,038
– – 0.02% 201
2021
Q4 		$518K Sell
2,038
-72
-3% -$21.1K 0.02% 179
2021
Q3 		$812K Sell
2,110
-130
-6% -$47.9K 0.03% 139
2021
Q2 		$526K Sell
2,240
-5
-0.2% -$894 0.02% 176
2021
Q1 		$294K Hold
2,245
– – 0.01% 210
2020
Q4 		$235K Buy
+2,245
New +$227K 0.01% 218

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Chicago Capital's MRNA Position: Q3 2024 in Review

Chicago Capital sold out of Moderna (MRNA) in Q3 2024, closing a stake of 1,955 shares — an estimated $232K sold.

Chicago Capital first reported a position in MRNA in Q4 2020 and held it in 15 quarters. The position peaked at $812K in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Chicago Capital reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Chicago Capital sold 1,955 Moderna shares in Q3 2024, an estimated $232K.
  • Chicago Capital first reported a position in Moderna in Q4 2020 and held it in 15 quarters.
  • Chicago Capital's Moderna position peaked at $812K in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Chicago Capital's 13F filing for Q3 2024, filed 18 Oct 2024.